Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination
Authors
Keywords
-
Journal
Expert Review of Anti-Infective Therapy
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2020-04-16
DOI
10.1080/14787210.2020.1756775
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae
- (2019) William R. Wilson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates
- (2019) Amit Kaushik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis
- (2019) Wesley D Kufel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis
- (2019) Matteo Bassetti et al. ADVANCES IN THERAPY
- The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
- (2019) Ilias Karaiskos et al. Frontiers in Public Health
- In Vitro Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens
- (2019) Lindsay J. Caverly et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections
- (2019) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa
- (2019) Sophonie Jean et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections
- (2019) Chih-Cheng Lai et al. Journal of Clinical Medicine
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- (2018) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects
- (2018) Christopher M. Rubino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment
- (2018) Christopher M. Rubino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime/avibactam, Meropenem/vaborbactam or both? Clinical and formulary considerations
- (2018) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae
- (2018) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- Management of KPC-producing Klebsiella pneumoniae infections
- (2018) M. Bassetti et al. CLINICAL MICROBIOLOGY AND INFECTION
- Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae
- (2018) Young R. Lee et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Meropenem–vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria
- (2018) Twisha S Patel et al. Future Microbiology
- In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
- (2018) Michael A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection
- (2018) Keith S. Kaye et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: Systematic review and meta-analysis
- (2018) Jorge A. Ramos-Castañeda et al. JOURNAL OF INFECTION
- Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae
- (2018) Sarah Christina Jane Jorgensen et al. PHARMACOTHERAPY
- Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
- (2018) Sohita Dhillon DRUGS
- Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
- (2018) David C. Griffith et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient
- (2018) Vasilios Athans et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model
- (2018) Mojgan Sabet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of the Meropenem Component of Meropenem‐Vaborbactam in the Treatment of KPC ‐Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient
- (2018) Alexandra M. Hanretty et al. PHARMACOTHERAPY
- Game Changers: New β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria
- (2017) Karen Bush ACS Infectious Diseases
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects
- (2016) David C. Griffith et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
- (2016) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
- (2016) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory
- (2016) Mordechai Grupper et al. CLINICAL MICROBIOLOGY REVIEWS
- Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
- (2016) Jason M. Pogue et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams
- (2016) Dustin T. King et al. PROTEIN SCIENCE
- Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
- (2015) Eric Wenzler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens
- (2015) David P. Nicolau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
- (2015) Scott J. Hecker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Seizures as adverse events of antibiotic drugs
- (2015) Raoul Sutter et al. NEUROLOGY
- In VitroActivity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria
- (2013) Ellie J. C. Goldstein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
- (2013) David E. Ehmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epileptogenic Potential of Carbapenem Agents: Mechanism of Action, Seizure Rates, and Clinical Considerations
- (2011) April D Miller et al. PHARMACOTHERAPY
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetic and Pharmacodynamic Parameters of Antimicrobials
- (2009) Chiara Adembri et al. CLINICAL PHARMACOKINETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started